Storia in 4 fonti

Zaynich's blockbuster potential lifts Wockhardt's long-term outlook

Wockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of net losses. The drug, targeting multidrug-resistant bacteria, has a projected peak sales of $1.5 billion, potentially transforming the company's financial outlook. Investors have responded positively, with the stock surging on the news.

Raccontata da

economictimes.indiatimes.com

thehindubusinessline.com

morningstar.com

timesofindia.indiatimes.com

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

economictimes.indiatimes.com3 mesi fa

If you have the patience, you can achieve innovation milestones, says Wockhardt chairman Habil Khorakiwala

Wockhardt wins FDA approval for Zaynich antibiotic, targeting $1.5-2B peak sales and 20% market share in the $9B AMR space. Long-term R&D beats quarterly cycles. For CTOs, biotech's shift to AI-driven discovery signals where enterprise tech investment flows next.

Leggi questa versione → originale

Timeline cronologica

sabato 30 maggio 2026·economictimes.indiatimes.com
Wockhardt secures US FDA approval for antibiotic Zaynich
Wockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. This breakthrough drug targets superbugs…
lunedì 1 giugno 2026·economictimes.indiatimes.com
FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics market
Wockhardts newly approved antibiotic Zaynich has the potential to transform the treatment of drug-resistant infections, according to Mahesh Patel, the scientist behind the drug.…

Zaynich's blockbuster potential lifts Wockhardt's long-term outlook

Confronto fonti

If you have the patience, you can achieve innovation milestones, says Wockhardt chairman Habil Khorakiwala

Timeline cronologica

Wockhardt secures US FDA approval for antibiotic Zaynich

FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics market

'USFDA nod for Zaynich a major boost'

Wockhardt marks research milestone with USFDA approval for novel antibiotic Zaynich

Wockhardt Receives U.S. FDA Approval for ZAYNICH™ (cefepime and zidebactam), a Novel Intravenous Antibiotic…

Wockhardt shares in focus after FDA approval for antibiotic targeting drug-resistant infections. Check details

Wockhardt marks research milestone with USFDA approval for novel antibiotic Zaynich

Wockhardt Receives U.S. FDA Approval for ZAYNICH™ (cefepime and zidebactam), a Novel Intravenous Antibiotic for the Treatment of Adult…

If you have the patience, you can achieve innovation milestones, says Wockhardt chairman Habil Khorakiwala

'USFDA nod for Zaynich a major boost'

Zaynich's blockbuster potential lifts Wockhardt's long-term outlook

Wockhardt shares tumble 9% amid profit booking after sharp rally on Zaynich approval

Wockhardt shares pause massive 36% rally in 5 sessions; slip 7%. What’s behind the selloff?